Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Organon & Co. Common Stock — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $34.66 (market cap $116.11M), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 31.2× Roundhill NVDA WeeklyPay ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Roundhill NVDA WeeklyPay ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill NVDA WeeklyPay ETF for 52 Days and Organon & Co. Common Stock for 0 Days on average.
| NVDW | OGN | |
|---|---|---|
Market Cap | $116.11M | $3.62B |
Volume | 41,612 | 2,892,999 |
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $13.81 |
52-Week Low | $31.88 | $5.70 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $36.64 with minimal daily movement (+0.14%). Technical indicators show a bearish trend with strong sell signals from moving averages, though RSI suggests potential oversold conditions. The ETF generates weekly dividend income from Nvidia exposure but carries leverage risks. Recent news highlights its high-yield potential amid Nvidia's strong earnings performance.
The outlook remains cautious due to leveraged structure and dependency on Nvidia volatility. While weekly dividends offer income appeal, NAV erosion during Nvidia downturns presents significant risk. Investors should weigh high yield potential against elevated volatility exposure in this specialized income vehicle.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
